Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
See More
BD Horizon™ BV421 Mouse Anti-Human CD135
Clone 4G8 (RUO)
Flow cytometric analysis of CD135 expression on human REH cells. Cells from the human REH (Acute B cell leukemia, ATCC CRL-8283) cell line were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dashed line histogram) or BD Horizon BV421 Mouse Anti-Human CD135 antibody (Cat. No. 564708; solid line histogram). The fluorescence histogram showing CD135 expression (or Ig Isotype control staining) was derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Flow cytometric analysis of CD135 expression on human REH cells. Cells from the human REH (Acute B cell leukemia, ATCC CRL-8283) cell line were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dashed line histogram) or BD Horizon BV421 Mouse Anti-Human CD135 antibody (Cat. No. 564708; solid line histogram). The fluorescence histogram showing CD135 expression (or Ig Isotype control staining) was derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Product Details
BD Horizon™
FLK2; FLT-3; Fms-related tyrosine kinase 3; STK-1
Human (QC Testing)
Mouse BALB/c IgG1, κ
Human FLT3 Transfected Cell Line
Flow cytometry (Routinely Tested)
5 µl
VI C-27
AB_2738906
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO
Preparation And Storage
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV421 under optimum conditions, and unconjugated antibody and free BD Horizon BV421 were removed.
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
Stain Buffer (FBS) RUO
Size
500 ML
Cat No.
554656
Stain Buffer (BSA) RUO
Size
500 ML
Cat No.
554657
BV421 Mouse IgG1, k Isotype Control RUO
Size
50 µg
Cat No.
562438
566256 Rev. 1
Antibody Details
4G8
The 4G8 monoclonal antibody specifically binds to CD135 which is also known as FMS-like tyrosine kinase 3 (FLT3), Fetal liver kinase 2 (FLK2) and Stem cell tyrosine kinase 1 (STK1). CD135 is a 155-160 kDa type I transmembrane glycoprotein. It belongs to subclass III of the receptor tyrosine kinase (RTK) family which includes receptors for M-CSF (CD115), SCF/c-Kit Ligand (CD117), and PDGF (CD140a and CD140b). CD135 is expressed on multipotential, myelomonocytic and primitive B-cell progenitors. The most primitive hematopoietic progenitor cells express low levels of CD135. CD135 plays the role of growth factor receptor for early hematopoietic progenitors. Reports from studies with knockout mice have shown that targeted CD135 disruption impaired the development of primitive progenitor cells of all hematopoietic lineages with significant impact on lymphopoietic precursors.
The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.
566256 Rev. 1
Format Details
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
BV421
407 nm
423 nm
566256 Rev.1
Citations & References
View product citations for antibody "566256" on CiteAb
Development References (7)
-
Bürhring H-J, Birnbaum D, Brasel KA, et al. CD135 (FLT3/FLK2/STK-1) Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:875-879.
-
Lyman SD, James L, Johnson L. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood. 1994; 83(10):2795-27801. (Biology). View Reference
-
Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995; 3(1):147-161. (Biology). View Reference
-
Rappold I, Bürhring H-J. CD135 Workshop: Functional aspects and reactivity of FLT3-specific antibodies. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:879-881.
-
Rappold I, Ziegler BL, Kohler I, et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997; 90(1):111-125. (Immunogen: ELISA, Flow cytometry, Immunoprecipitation). View Reference
-
Rosnet O, Schiff C, Pébusque MJ. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993; 82(4):1110-1119. (Biology). View Reference
-
Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood. 1996; 87(4):1317-1325. (Biology). View Reference
566256 Rev. 1
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.